Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.

Baber, Usman; Giustino, Gennaro; Sartori, Samantha; Aquino, Melissa; Stefanini, Giulio; Steg, P Gabriel; Windecker, Stephan; Leon, Martin B; Wijns, William; Serruys, Patrick W; Valgimigli, Marco; Stone, Gregg W; Dangas, George D; Morice, Marie-Claude; Camenzind, Edoardo; Weisz, Giora; Smits, Pieter C; Kandzari, David; Von Birgelen, Clemens; Mastoris, Ioannis; ... (2016). Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC. Cardiovascular Interventions, 9(1), pp. 28-38. Elsevier 10.1016/j.jcin.2015.09.023

[img] Text
1-s2.0-S1936879815015757-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

OBJECTIVES

This study sought to evaluate: 1) the effect of impaired renal function on long-term clinical outcomes in women undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES); and 2) the safety and efficacy of new-generation compared with early-generation DES in women with chronic kidney disease (CKD).

BACKGROUND

The prevalence and effect of CKD in women undergoing PCI with DES is unclear.

METHODS

We pooled patient-level data for women enrolled in 26 randomized trials. The study population was categorized by creatinine clearance (CrCl) <45 ml/min, 45 to 59 ml/min, and ≥60 ml/min. The primary endpoint was the 3-year rate of major adverse cardiovascular events (MACE). Participants for whom baseline creatinine was missing were excluded from the analysis.

RESULTS

Of 4,217 women included in the pooled cohort treated with DES and for whom serum creatinine was available, 603 (14%) had a CrCl <45 ml/min, 811 (19%) had a CrCl 45 to 59 ml/min, and 2,803 (66%) had a CrCl ≥60 ml/min. A significant stepwise gradient in risk for MACE was observed with worsening renal function (26.6% vs. 15.8% vs. 12.9%; p < 0.01). Following multivariable adjustment, CrCl <45 ml/min was independently associated with a higher risk of MACE (adjusted hazard ratio: 1.56; 95% confidence interval: 1.23 to 1.98) and all-cause mortality (adjusted hazard ratio: 2.67; 95% confidence interval: 1.85 to 3.85). Compared with older-generation DES, the use of newer-generation DES was associated with a reduction in the risk of cardiac death, myocardial infarction, or stent thrombosis in women with CKD. The effect of new-generation DES on outcomes was uniform, between women with or without CKD, without evidence of interaction.

CONCLUSIONS

Among women undergoing PCI with DES, CKD is a common comorbidity associated with a strong and independent risk for MACE that is durable over 3 years. The benefits of newer-generation DES are uniform in women with or without CKD.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Stefanini, Giulio, Windecker, Stephan, Valgimigli, Marco

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1876-7605

Publisher:

Elsevier

Language:

English

Submitter:

Daria Vogelsang

Date Deposited:

15 Apr 2016 10:31

Last Modified:

05 Dec 2022 14:53

Publisher DOI:

10.1016/j.jcin.2015.09.023

PubMed ID:

26762908

Uncontrolled Keywords:

chronic kidney disease; drug-eluting stents; outcomes; women

BORIS DOI:

10.7892/boris.78559

URI:

https://boris.unibe.ch/id/eprint/78559

Actions (login required)

Edit item Edit item
Provide Feedback